GLAXO - IntraDay Trade Analysis with Live Signals

Last Updated Time : 20 Dec 25, 07:02 am

IntraDay Trade Rating: 3.9

📊 Analysis: GLAXO shows moderate intraday potential with strong fundamentals but neutral technicals. Current price (₹2,540) is below both the 50 DMA (₹2,605) and 200 DMA (₹2,715), reflecting short-term weakness. RSI at 47.8 indicates balanced momentum, while MACD (1.22) suggests mild bullishness. Volume (70k) is slightly below the weekly average (74k), showing limited intraday participation. Strong ROCE and ROE provide fundamental support, but valuation remains stretched compared to industry peers.

💡 Optimal Buy Price: ₹2,530–₹2,545 (near support zone).

🎯 Profit Exit Levels: ₹2,580 (first resistance), ₹2,610 (second resistance).

🛡️ Stop-Loss: ₹2,510 (below intraday support).

⏱️ If Already Holding: Exit intraday if price fails to sustain above ₹2,540 or if volume weakens further. Consider booking profits near ₹2,580–₹2,610 if momentum improves during the session.

Positive

• 📈 ROCE (62.6%) and ROE (46.4%) highlight exceptional capital efficiency.
• 💰 Debt-to-equity (0.02) ensures strong financial stability.
• 📊 Quarterly PAT growth from ₹205 Cr. to ₹253 Cr. (3.15% variation).
• 💵 Dividend yield (1.68%) adds shareholder value.

Limitation

• ⚠️ Current price below DMA levels reflects short-term weakness.
• 📉 High P/E (45.4) compared to industry average (30.6), suggesting overvaluation.
• 📊 PEG ratio (-2.29) highlights unsustainable growth prospects.
• 🌍 FII holding decreased (-0.10%), showing foreign investor caution.
• 📉 52-week index (38.8%) reflects weak relative performance.

Company Negative News

• 📰 No major negative news reported, but valuation concerns and weak technicals weigh on sentiment.

Company Positive News

• 📰 Quarterly profit growth supports positive sentiment despite valuation concerns.
• 📊 DII inflows (+0.04%) add confidence to fundamentals.

Industry

• 🏭 Pharma sector trading at PE 30.6, lower than GLAXO’s valuation (45.4).
• 📈 Industry demand supported by healthcare expansion and consumer health product growth.

Conclusion

⚖️ GLAXO is fundamentally strong with excellent ROCE, ROE, and profit growth, but intraday signals are mixed due to weak DMA positioning and valuation concerns. Cautious entry near ₹2,530–₹2,545 with profit exits at ₹2,580–₹2,610 is possible, while maintaining a strict stop-loss at ₹2,510.

Would you like me to extend this into a peer benchmarking overlay comparing GLAXO with other pharma and healthcare stocks, or should we focus on basket rotation signals for intraday workflow optimization?